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ORIGINAL ARTICLE
Wheat-derived arabinoxylan oligosaccharides with prebiotic
effect increase satietogenic gut peptides and reduce metabolic
endotoxemia in diet-induced obese mice
AM Neyrinck1, VF Van He´e1, N Piront2, F De Backer1, O Toussaint2, PD Cani1 and NM Delzenne1
BACKGROUND: Alterations in the composition of gut microbiota ---known as dysbiosis--- have been proposed to contribute to the
development of obesity, thereby supporting the potential interest of nutrients acting on the gut microbes to produce beneﬁcial
effect on host energetic metabolism. Non-digestible fermentable carbohydrates present in cereals may be interesting nutrients
able to inﬂuence the gut microbiota composition.
OBJECTIVE AND DESIGN: The aim of the present study was to test the prebiotic potency of arabinoxylan oligosaccharides
(AXOS) prepared from wheat bran in a nutritional model of obesity, associated with a low-grade chronic systemic inﬂammation.
Mice were fed either a control diet or a high fat (HF) diet, or a HF diet supplemented with AXOS during 8 weeks.
RESULTS: AXOS supplementation induced caecal and colon enlargement associated with an important biﬁdogenic effect.
It increased the level of circulating satietogenic peptides produced by the colon (peptide YY and glucagon-like peptide-1), and
coherently counteracted HF-induced body weight gain and fat mass development. HF-induced hyperinsulinemia and the
Homeostasis Model Assessment of insulin resistance were decreased upon AXOS feeding. In addition, AXOS reduced
HF-induced metabolic endotoxemia, macrophage inﬁltration (mRNA of F4/80) in the adipose tissue and interleukin 6 (IL6)
in the plasma. The tight junction proteins (zonula occludens 1 and claudin 3) altered upon HF feeding were upregulated by
AXOS treatment suggesting that the lower inﬂammatory tone was associated with the improvement of gut barrier function.
CONCLUSION: Together, these ﬁndings suggest that speciﬁc non-digestible carbohydrates produced from cereals such as AXOS
constitute a promising prebiotic nutrient in the control of obesity and related metabolic disorders.
Nutrition and Diabetes (2012) 2, e28; doi:10.1038/nutd.2011.24; published online 23 January 2012
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INTRODUCTION
In most Western countries, obesity and related diseases, such as
diabetes and cardiovascular diseases, have emerged as major
health problems. In parallel, the consumption of cereals ---
representing a major source of dietary ﬁbres--- has decreased
dramatically in Western countries over the last century.1 It has
been suggested that the decrease in ﬁbre intake contributes to
the development of these health disorders.2 - 4 Studies performed
in rodents and humans suggest that obesity is associated with an
altered composition of gut microbiota.5 - 10 Several mechanisms
are proposed, linking events occurring in the gut upon
carbohydrate fermentation and the control of metabolic
disorders.7,8,11 - 14 Changes in the synthesis of gastrointestinal
peptides controlling food intake (glucagon like peptide-1
(GLP-1), peptide YY (PYY), ghrelin, amylin, pancreatic polypeptide)
occur. The regulation of fat storage takes place namely through
modiﬁcation of intestinal expression of the lipoprotein lipase
inhibitor, fasting-induced adipose factor. Energy sparing is partly
due to the fermentation of non-digestible carbohydrates into
short chain fatty acids that are used by host tissues. The release of
bacterial metabolites (short chain fatty acids, conjugated
linoleic acid) allow them to act as regulators of adiposity
(via G-protein-coupled receptors (GPR43) and/or peroxisome
proliferator-activated receptor-g (PPARg)-dependent mechan-
isms). Finally, the changes in the activity of peptides/systems
involved in the control of gut permeability and metabolic
endotoxemia (glucagon like peptide-2 (GLP-2), tight junction
proteins such as zonula occludens-1 (ZO1), endocannabinoid
system,) also contribute to modulate host metabolic alterations,
such as inﬂammation and endotoxemia. Inulin and fructooligo-
saccharides are non-digestible carbohydrates obtained from
chicory root. We have previously shown that those inulin-type
fructans restored the drop of biﬁdobacteria occurring in the
caeco-colon of high-fat (HF) diet-fed mice. They improve
metabolic alterations induced by HF feeding including dyslipide-
mia, impaired gut permeability, metabolic endotoxemia and
diabetes.7,8,14 - 16 These effects are largely dependent on the
production and action of gut-derived peptides, such as GLP-1 and
GLP-2 actions.14,16 Inulin-type fructans are typically studied as they
were the ﬁrst compounds to respond to the prebiotic concept.
Prebiotic is deﬁned as the selective stimulation of growth and/or
activity of one or a limited number of microbial genus(era)/species
in the gut microbiota that confer(s) health beneﬁts to the host.17
Other non-digestible/fermented carbohydrates gradually fermen-
ted throughout the colon can be prepared from cereals. They may
be valuable nutrients that could improve health thanks to their
inﬂuence on gut microbiota composition.
Received 13 December 2011; accepted 18 December 2011
1Universite´ catholique de Louvain, Louvain Drug Research Institute, Metabolism and Nutrition Research Group, Brussels, Belgium and 2University of NAMUR - FUNDP,
URBC - NARILIS, Namur, Belgium. Correspondence: Professor NM Delzenne, Universite´ catholique de Louvain, Louvain Drug Research Institute, Metabolism and Nutrition Research
Group, Avenue Mounier 73, box B1.73.11, B-1200 Brussels, Belgium.
E-mail: nathalie.delzenne@uclouvain.be
Citation: Nutrition and Diabetes (2012) 2, e28; doi:10.1038/nutd.2011.24
& 2012 Macmillan Publishers Limited All rights reserved 2044-4052/12
www.nature.com/nutd
The most important non-digestible carbohydrates present in
wheat are the non-starch polysaccharides arabinoxylans. Arabino-
xylans represent 50% of dietary ﬁbres present in wheat bran.18,19
Of particular interest, the highly polymerised arabinoxylan from
bran may be hydrolysed through wheat-associated endoxylanases
or speciﬁc intestinal bacteria possessing arabinoxylan-degrading
enzymes. This hydrolysis leads to the formation of arabinoxylan
oligosaccharides (AXOS). AXOS represent a new class of candidate
prebiotics depending on their structure (degree of polymerisation
and degree of arabinose substitution).18,20 Little information is
available on the prebiotic potency of AXOS in vivo. One study
compared the prebiotic effects of AXOS and inulin using simulator
of the human intestinal microbial ecosystem.21 The authors
demonstrated that AXOS fermentation and short chain fatty acid
production took place in the more distal colon region as
compared with the place where inulin fermented. AXOS
fermentation results also in a strong propionate production
suggesting that this prebiotic might be a good prebiotic
candidate to impact fat metabolism in the host.21 The aim of
the present study was to assess the effect of AXOS prepared from
wheat bran on diet-induced obesity and inﬂammation.
MATERIALS AND METHODS
Animals and diet intervention
Twenty-four male C57bl6/J mice (9-week-old at the beginning of the
experiment, Charles River Laboratories, Lyon, France) were housed in
groups of four per cage in a controlled environment (12-h daylight cycle)
with free access to food and water. After 1 week of acclimatisation, the
mice were divided into three groups (n¼ 8 per group): a control group
(CT), fed with a control diet (A04, SAFE, Villemoison-sur-Orge, France), a
group fed a HF diet and a group fed the same HF diet, supplemented with
AXOS (92.5% HF (w/w)þ 7.5%AXOS extract; HF-AXOS group). The
composition of both the HF diet (D12492, Research Diets, New Brunswick,
NJ, USA) and the A04 standard diet is presented in Supplementary
Information 1. The caloric value of the diets were 3.1 Kcal g1, 5.2 Kcal g1
and 5.0 Kcal g1 for CT, HF and HF-AXOS diets, respectively. Cosucra
groupe (Warcoing, Belgium) supplied an extract of AXOS with a purity of
75% and a degree of substitution arabinose/xylose of 0.2 - 0.3. HPSEC
analysis shows that 75% of the AXOS preparation have a molecular weight
below 5900Da. Food intake was recorded twice a week, taking into
account the amount of diet eaten by four mice kept in the same cage, and
by deducing food spillage. The results are presented for the whole study
and represent the sum of the diet consumed during 8 weeks for four mice.
The total caloric intake was obtained by multiplying total food intake (g)
for four mice per cage (n¼ 2) by the caloric value of the diets. After 8
weeks of dietary treatment and after a period of fasting (6 h), mice were
anesthetised (intra peritoneal administration of 100mg kg1 ketamine and
10mg kg1 xylazine) and blood samples were harvested for further
analysis. Portal blood was taken in o30 sec and directly ﬂushed within
tubes containing dipeptidyl peptidase IV (DPPIV) inhibitor (Millipore,
St Charles, MO, USA) and a cocktail of general protease inhibitors
containing EDTA, bestatin, leupeptin, aprotinin, E-64 and 4-(2-aminoethyl)-
benzenesulfonyl ﬂuoride hydrochloride (P2714-Sigma protease cocktail,
Sigma, Saint Louis, MO, USA and Roche Pefabloc SC, Roche Diagnostics,
Vilvoorde, Belgium). Plasma was immediately removed and stored within
tubes containing the same protease inhibitors at 80 1C for gut peptide
determination. Liver, adipose tissues (visceral, epididymal and subcuta-
neous), proximal colon and caecum were carefully dissected, weighed and
immersed in liquid nitrogen before storage at 80 1C. Mouse experiment
was approved by and performed in accordance with the guidelines of the
local ethics committee. Housing conditions were speciﬁed by the Belgian
Law of 6 April 2010, regarding the protection of laboratory animals
(Agreement LA1230314).
Blood parameters
Plasma insulin concentrations were determined using an ELISA kit
(Mercodia, Uppsala, Sweden). The Homeostasis Model Assessment of
insulin resistance (HOMA-IR) was calculated by the following formula:
(HOMA-IR)¼ [fasting glycemia (mM)] [fasting insulinemia (pM)]/22.5.22
Plasma triglycerides, cholesterol and non-esteriﬁed fatty acid concentra-
tions were measured using kits coupling enzymatic reaction and spectro-
photometric detection of reaction end products (Diasys Diagnostic and
Systems, Holzheim, Germany). High-density lipoprotein cholesterol con-
centration was measured enzymatically after precipitation of other
lipoproteins, such as very-low-density lipoprotein, chylomicrons and
low-density lipoprotein cholesterol (Diasys Diagnostic and Systems).
Low-density lipoprotein was estimated by the Friedewald formula.23
Systemic concentrations of interleukins (IL6, IL1a, IL1b, IL10, IL13),
tumour necrosis factor alpha and monocyte chemotactic protein 1 were
determined in 15 ml of plasma using a multiplex immunoassay kit (Bio-Plex
Cytokine Assay, Bio-Rad, Nazareth, Belgium) and measured using Luminex
technology (Bioplex, Bio-Rad). Portal concentrations of glucagon-like
peptide 1 (GLP-1), PYY, amylin, pancreatic polypeptide, ghrelin and leptin
were determined in 15ml of plasma using a multiplex immunoassay kit
(Bio-Plex Pro Assay, Bio-Rad) and measured using Luminex technology
(Bioplex, Bio-Rad). Portal lipopolysaccharides (LPS) concentration was
measured by using Endosafe-MCS (Charles River Laboratories) based
on the limulus amaebocyte lysate kinetic chromogenic methodology
that measures color intensity directly related to the endotoxin concen-
tration in a sample. Serum were diluted 1/10 with endotoxin-free
buffer to minimise interferences in the reaction (inhibition or enhance-
ment) and heated for 15min at 70 1C. Each sample was diluted with
endotoxin-free limulus amaebocyte lysate reagent water (Charles River
Laboratories) and treated in duplicate and two spikes for each sample were
included in the determination. All samples have been validated for the
recovery and the Coefﬁcient Variation. The lower limit of detection was
0.01EUml1.24
Lipid analysis in the liver
Triglycerides and cholesterol were measured in the liver tissue after
extraction with chloroform- methanol, as described by Neyrinck et al.25
Brieﬂy, 100mg of liver tissue was homogenised in 1ml of phosphate buffer
(pH 7.4). Lipids were extracted by mixing 125ml of homogenate with 1ml
of chloroform:methanol (2:1). The chloroform phase was evaporated
under nitrogen ﬂux and the dried residue was solubilised in 100ml
of isopropanol. Triglycerides and total cholesterol were measured as
previously described for plasma samples.
Microbial analysis of the caecal contents and expression of
selected genes in tissues
At the end of the experiment, the total caecum content was collected and
weighed before storage at 80 1C. Quantitative PCR (Q-PCR) for
Biﬁdobacterium spp., Lactobacillus spp., Bacteroides-Prevotella spp. were
performed as reported by Neyrinck et al.26 using Mesa Fast qPCR
(Eurogentec, Seraing, Belgium). Primers are detailed in Supplementary
Information 2. We have applied the ampliﬁcation programme
recommended by the manufacturers; the annealing temperature
being 58 1C. Real-time PCRs were performed with the StepOnePlus
real-time PCR system and software (Applied Biosystems, Den Ijssel, The
Netherlands).
Total RNA was isolated from tissues (colon and visceral adipose tissue)
using the TriPure isolation reagent kit (Roche Diagnostics). Complementary
DNA (cDNA) was prepared by reverse transcription of 1 mg total RNA using
the Kit Reverse transcription System (Promega, Leiden, The Netherlands).
Real-time PCRs were performed with the StepOnePlus real-time PCR
system and software (Applied Biosystems, The Netherlands) using Mesa
Fast qPCR (Eurogentec) for detection according to the manufacturer’s
instructions. RPL19 RNA was chosen as housekeeping gene. Primer
sequences for the targeted mouse genes are detailed in Supplemen-
tary Information 2. All samples were run in duplicate in a single 96-well
reaction plate and data were analysed according to the 2-DCT method.
The identity and purity of the ampliﬁed product was checked through
analysis of the melting curve carried out at the end of ampliﬁcation.
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TaqMan low-density array performed on reverse-transcribed RNA
samples extracted from the colon
Low-density DNA array on-demand was used to detect 48 different
transcript species and conﬁgured into eight identical 48-transcript sets
(Applied Biosystems, Foster City, CA, USA). Three reliable housekeeping
transcripts -RPL19, GAPDH and 18S- were chosen in this model as
reference transcripts for normalisation. Forty-ﬁve other transcripts of
interest were chosen as their translation products are involved in
inﬂammation, lipid metabolism, short chain fatty acid response, gut
permeability, gut peptide production and response, cell differentiation
and endocannabinoid system. Total RNA was isolated using the TriPure
isolation reagent kit (Roche Diagnostics). Total RNA (2mg) was reverse-
transcribed using the high-capacity cDNA Archive Kit (Applied Biosystems,
USA) following manufacturer’s instructions. A total of 49ml RNase/DNase-
free water with 1 ml cDNA (100 ng of retrotranscribed total RNA) and
50ml TaqMan Universal PCR Master Mix (Applied Biosystems, USA) was
added to each line of LDA. LDA was sealed before centrifugation in
a Heraus Multifuge 3S centrifuge (Cardinal Health, Dublin, OH, USA) for
1min 4 at 1200 r.p.m. The PCR ampliﬁcations were performed in a
7900HT Fast Real-Time PCR system: 10min at 94.5 1C, followed by 40 cycles
of denaturation at 97 1C for 30 s and annealing/extension at 59.7 1C for
1min. mRNA abundances values were normalised to the expression value
of RPL19 and calculations based on the comparative Ct (cycle threshold)
method (2DDCt ). Results were presented as the fold change relative to the
control mice and we have also presented the ratio between the HF-AXOS
group versus the HF group.
Statistical analysis
Results are presented as mean±s.e.m. Statistical analysis was performed
by analysis of variance (ANOVA) followed by post hoc Tuckey’s multiple
comparison test (GraphPad Software, San Diego, CA, USA). Correlations
between parameters were assessed by Pearson’s correlation test. Po0.05
was considered as statistically signiﬁcant. Principal component analysis
and hierarchical clustering heat map proﬁle were performed using and
JMP 8.0.1 (SAS Campus Drive, Cary, NC, USA).
RESULTS
Supplementation with AXOS decreases body weight gain, caloric
intake and fat mass development
The ﬁnal body weight of mice was 28.7±0.6, 36.7±1.0* and
32.4±0.6 g*y for CT, HF and HF-AXOS group, respectively
(*Po0.05 versus CT and yPo0.05 versus HF, ANOVA).
The HF diet, due to its higher energy density (5.2 versus
3.1 Kcal g1 for the control diet) signiﬁcantly increased body
weight gain and the development of epididymal, visceral and
subcutaneous fat as compared with CT group (Figure 1). AXOS
supplementation in the HF diet decreased energy density of the
diet (5.0 Kcal g1) and decreased body weight gain by about 37%
compared with HF group (Figure 1b). AXOS treatment also
decreased fat mass in a signiﬁcant way in the epididymal and
subcutaneous adipose tissues compared with HF treatment alone
(Figures 1d and e). The weight of subcutaneous adipose tissue
came back to the control value in HF-AXOS mice. The total caloric
intake, obtained by multiplying total food intake (measured
during 8 weeks) by the caloric value of the diets, was higher in HF
group than in controls (n¼ 2) (Figure 1c). This effect was blunted
when AXOS was added in the HF diet. The loss of body weight/fat
gain taking into account the caloric intake of mice revealed that
AXOS treatment did not signiﬁcantly decrease the HF-induced
feed efﬁciency (weight gain divided by calories consumed
during the whole treatment), which was 5.4±0.5, 11.1±0.9*
and 9.5±0.7* for CT, HF and HF-AXOS, respectively; *Po0.05
HF group versus CT group (ANOVA).
Supplementation with AXOS induces colon and caecal
enlargement and promotes the growth of biﬁdobacteria
HF feeding decreased the weight of caecal content, caecal tissue
and colon tissue as compared with the control condition (Figure
2a,b,c). Quantitative analysis in caecal content showed that HF diet
decreased the gram-positive biﬁdobacteria and lactobacilli as well
as the gram-negative bacteria such as Bacteroides --Prevotella spp.
(Figures 2d-- f). AXOS supplementation induced caecal and colon
enlargement together and produced a 2-log increase of the
biﬁdobacteria number in the caecal content as compared with
HF-fed mice. The weight of the colon and the weight of the caecal
content returned to the control values. The biﬁdogenic effect was
also signiﬁcant as compared with control mice. The number of
lactobacilli decreased upon HFþAXOS diet as compared with HF
diet alone or to the CT diet whereas the number of Bacteroides --
Prevotella spp. was not signiﬁcantly modiﬁed by AXOS treatment.
If we exclude the weight of the colon and the caecum, the ﬁnal
body weight of mice was 28.2±0.6, 36.4±1.0* and 31.9±0.6 g*y
for CT, HF and HF-AXOS group, respectively (*Po0.05 versus CT
and yPo0.05 versus HF, ANOVA).
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Figure 1. Body weight evolution (a), body weight gain (b), caloric intake (c) and weight of epididymal (d), subcutaneous (e) and visceral
(f ) adipose tissues of mice fed a control diet (CT), a high fat diet (HF) or a HF diet supplemented with arabinoxylan oligosaccharides (HF-AXOS)
for 8 weeks. *Po0.05 versus CT and yPo0.05 versus HF (ANOVA).
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Supplementation with AXOS does not modify lipid contents in the
serum and in the liver but decreased hyperinsulinemia and the
HOMA-IR
Lipids (triglycerides and cholesterol) in the serum and in the liver
were not signiﬁcantly affected by HF feeding and/or AXOS
supplementation (Supplementary Information 3). HF feeding
increased signiﬁcantly insulinemia and the HOMA-IR (Supplemen-
tary Information 3). AXOS treatment was able to blunt both
hyperinsulinemia and HF-increased HOMA-IR as values returned to
the control values.
Supplementation with AXOS modiﬁes gut peptides regulating
food intake
We have measured a panel of hormones regulating appetite that
were secreted by the adipose tissue (leptin), by the pancreas (amylin
and pancreatic polypeptide), by the stomach (ghrelin) or by the
intestinal L-cells (PYY and GLP-1) (Figure 3). The levels of gut
hormones, such as PYY, GLP-1, pancreatic polypeptide and ghrelin,
were decreased in the plasma 8 weeks after HF diet; this effect being
signiﬁcant for PYY. In contrast, the adipokine leptin signiﬁcantly
increased upon HF feeding. When AXOS was included in the HF diet,
we observed higher concentration of PYY with a mean value near
from the control value (Po0.05 HF-AXOS versus HF group, ANOVA).
We detected levels of GLP-1 in ﬁve HF-AXOS mice of seven with a
mean value of 55±21pgml1, whereas only one HF mouse of
seven had detectable GLP-1 concentration of 33pgml1 (Po0.05,
Chi-square test, HF-AXOS versus HF group). The effects of AXOS on
other gut peptides were not signiﬁcant. These results suggest that
AXOS promote gut peptides (PYY and GLP-1) coming from the
colon, which are able to regulate food intake by increasing satiety.
Supplementation with AXOS decreases inﬂammatory markers
induced upon HF feeding
We observed higher levels of proinﬂammatory mediators such as
IL6 in the plasma upon HF feeding (Table 1). AXOS supplementa-
tion signiﬁcantly decreased IL6 concentrations in the plasma as
compared with HF-fed mice, at a level near the control value.
Plasma IL6 negatively correlates with Biﬁdobacterium spp.
(r¼0.48; Po0.05 Pearson’s r correlation). In accordance with
inﬂammatory parameters measured in the plasma, AXOS supple-
mentation counteracted the HF-induced F4/80 expression in
visceral adipose tissue, suggesting a lower macrophage inﬁltration
in this tissue (F4/80 mRNA were 1.00±0.25, 2.47±0.45* and
1.18±0.32y for CT, HF and HF-AXOS groups respectively; *Po0.05
versus CT and yPo0.05 versus HF, ANOVA).
CT HF HF-AXOS
0.00
0.05
0.10
0.15
0.20
0.25
*
§
ca
ec
al
 c
on
te
nt
 (g
)
CT HF HF-AXOS
0.0
0.1
0.2
0.3
0.4
*
*§
ca
ec
al
 ti
ss
ue
 w
ei
gh
t
(%
 ve
rs
us
 bo
dy
 w
eig
ht
)
CT HF HF-AXOS
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
*
§
co
lo
n 
w
ei
gh
t
(%
 ve
rs
us
 bo
dy
 w
eig
ht
)
CT
8
9
10
11
*
*§
La
ct
ob
ac
ill
us
 s
pp
.
(ce
ll n
um
be
r/g
 of
 ca
ec
al
co
n
te
nt
)
CT
9.0
9.5
10.0
10.5
11.0
**
B
ac
te
ro
id
es
/P
re
vo
te
lla
ce
ll 
nu
m
be
r/g
 o
f c
ae
ca
l
co
n
te
nt
CT
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
*
*§
B
ifi
do
ba
ct
er
iu
m
 s
pp
.
ce
ll 
nu
m
be
r/g
 o
f c
ae
ca
l
co
n
te
nt
HF-AXOSHF HF-AXOSHF HF-AXOSHF
Figure 2. Weight of caecal content (a), caecal tissue (b) and colon tissue (c). Caecal bacterial content of Bifidobacterium spp.
(d), Lactobacillus spp. (e) and Bacteroides-Prevotella spp. (f ). Mice were fed a control diet (CT), a high fat diet (HF) or a HF diet supplemented
with arabinoxylan oligosaccharides (HF-AXOS) for 8 weeks. *Po0.05 versus CT and yPo0.05 versus HF (ANOVA).
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Supplementation with AXOS reduces endotoxemia and improves
gut barrier function
Given that inﬂammatory disorders occurring upon HF feeding are
related to alterations in gut permeability leading to metabolic
endotoxemia,14 we have quantiﬁed LPS in the portal blood and
we have measured the expression of a tight junction protein (ZO1)
in the colon. HF feeding decreased mRNA content of ZO1 in the
colon, whereas it increased the level of LPS in the portal blood
(Figure 4). AXOS supplementation counteracted the HF-induced
metabolic endotoxemia (Figure 4a). AXOS treatment signiﬁcantly
increased the level of ZO1 expression in the colon as compared
with HF group (Figure 4b). This suggests an improvement of gut
barrier function through AXOS treatment.
The role of the colon in the metabolic effect of AXOS
In this study, we highlighted several effects of AXOS suggesting
that the colon may be a key metabolic crossroad between the gut
microbiota and the management of metabolic parameters (colon
enlargement, higher circulating satietogenic peptides produced
by the L cells in the colon, higher expression of ZO1 in the colon).
We decided to explore several genes involved in inﬂammation,
lipid metabolism, short chain fatty acid response, gut permeability,
gut peptide production and response, cell differentiation and
endocannabinoid system using a TaqMan low-density array. This
technique allows for high throughput screening in functional
genomics by simultaneously measuring mRNA relative abun-
dances of multiple genes of interest.27 Among 48 cDNA species
analysed, 42 cDNA species were successfully ampliﬁed by LDA;
6 cDNA species were not detected or detected in few samples
(that is, interferon-gamma (IFNg), IL12, IL1a, IL4, macrophage
inﬂammatory protein alpha (MIP1a), glucose-dependent insulino-
tropic polypeptide (GIP)). Among transcript species in which
relative abundance could be analysed, eight transcript species
were signiﬁcantly and differentially abundant in proximal colon
upon HF feeding versus control diet. Six transcript species were
less abundant, in particular four genes encoding proteins involved
in gut barrier function (Table 2). AXOS treatment restored the
presence of three transcript species encoding tight junction
protein, with signiﬁcant abundance for the claudin 3 gene.
Although the abundance of transcript species encoding proin-
ﬂammatory cytokines was not signiﬁcantly affected by dietary
treatments (HF alone or HFþAXOS), we observed a signiﬁcant
upregulation of the anti-inﬂammatory cytokine IL10 as compared
with control mice. Of note, AXOS supplementation downregulated
fasting-induced adipose factor expression as compared with
either the control group or the HF group.
PCA
The results of PCA of all parameters ---related to gut bacteria, gut
peptide, colonic gene expression, gut barrier function, endotox-
emia, inﬂammatory markers, body weight, fat mass, lipid proﬁles
and glucose homeostasis--- analysed in this study are illustrated in
Figure 5a. The ﬁrst and the second principal components (PCs)
were responsible for only 39% of the total variance. The projection
of the parameters in the plane by these PC supported the
presence of a separate cluster for mice fed with a HF diet. PCA
revealed regrouping between control mice and AXOS-treated
mice. We performed a second PCA taking into account only
parameters signiﬁcantly modiﬁed by AXOS supplementation
(Figure 5b). The ﬁrst and the second PC explained, in this case,
61% of the total variance. Overall, PC1 was mainly characterised by
body weight gain, fat mass development, HOMA-IR and fasted
insulinemia with values up to 0.8 (right side), whereas PC2 was
mainly characterised by IL-10 expression in the colon and
lactobacilli content in the caecum with absolute values up to
0.5. In contrast, portal GLP-1 and PYY were situated on the left
side. Both portal LPS and circulating IL6 were in opposition to
biﬁdobacteria content in the caecum and expression of proteins
involved in tight junctions (ZO1 and claudin 3) in the colon. These
loadings were in accordance with Pearson’s correlation test (data
not shown). PC2 clearly discriminated between lactobacilli content
in the caecum and the expression of IL10 in the colon in
accordance with Pearson’s correlation test (r¼0.61; Po0.01).
DISCUSSION
The objective of the work performed in this paper, was to assess
the potential relevance for host health of the modulation of the
gut microbial composition occurring in obese mice upon
supplementation with fermentable carbohydrates produced from
cereals: the AXOS. We describe speciﬁc changes in gut microbiota
composition that occur upon AXOS feeding in vivo (increase in
biﬁdobacteria and decrease in lactobacilli), those effects being
associated with improvement of inﬂammation and of gut barrier
integrity in obese mice.
Table 1. Inflammatory markers in the plasma
CT HF HF-AXOS D(HF-AXOS-HF)
MCP-1 41±10 189±97 39±11 151
IL6 4.4±0.5 11.4±3.5 * 3.9±0.5y 8
IL1b 21±4 14±4 11±2 3
IL13 249±13 242±48 216±42 26
TNFa 89±9 67±14 63±12 4
IL1a 128±19 183±54 176±35 6
IL10 151±19 113±40 164±34 51
Abbreviations: CT, control diet; HF, high fat diet; HF-AXOS, HF diet
supplemented with arabinoxylan oligosaccharides; IL, interleukin;
MCP, monocyte chemoattractant protein; TNF, tumour necrosis factor.
Mice were fed a CT diet, a HF diet or a HF-AXOS diet for 8 weeks. *Po0.05
versus CT and yPo0.05 versus HF (ANOVA).
All values are expressed in pgml1.
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Figure 4. Plasma lipopolysaccharides (LPS) (a) and zonula occludens 1 (ZO1) expression in the colon (b) in mice fed a control diet (CT), a high
fat diet (HF) or a HF diet supplemented with arabinoxylan oligosaccharides (HF-AXOS) for 8 weeks. *Po0.05 versus CT and yPo0.05 versus HF
(ANOVA).
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Table 2. Gene expression profile identified by TLDA analysis in the proximal colon
Gene NM HF HF-AXOS Ratio
Inflammation
IL10 NM_010548.1 1.76±0.49 3.07±0.55* 1.75
TNFa NM_013693.2 0.58±0.14 0.89±0.18 1.53
MCP-1 NM_011333.3 0.91±0.06 1.22±0.47 1.34
TLR4 NM_021297.2 0.77±0.05* 1.00±0.10 1.31
IL6 NM_031168.1 0.79±0.09 0.98±0.23 1.24
COX2 NM_011198.3 0.78±0.12 0.94±0.13 1.20
IL7 NM_008371.4 0.96±0.05 1.09±0.11 1.14
PPARg NM_011146.2 0.76±0.06* 0.73±0.08* 0.95
CD14 NM_009841.3 1.27±0.13 1.08±0.12 0.85
MIP-1a NM_011337.2 ND ND ND
IL12a NM_008351.1 ND ND ND
IFNg NM_008337.3 ND ND ND
IL1a NM_010554.4 ND ND ND
IL4 NM_021283.1 ND ND ND
Permeability
Claudin 3 NM_009902.3 0.81±0.02* 1.03±0.08y 1.27
ZO2 NM_011597.3 0.77±0.04* 0.94±0.12 1.22
MUC-2 NM_023566.2 0.56±0.05* 0.67±0.11* 1.18
ZO1 NM_009386.1 0.79±0.06* 0.91±0.10 1.16
ITF NM_011575.1 1.03±0.04 1.07±0.08 1.03
Occludin NM_008756.2 0.86±0.06 0.82±0.07 0.95
Claudin 2 NM_016675.3 0.75±0.07 0.63±0.14 0.84
Differentiation
Neurog3 NM_009719.6 0.91±0.10 1.08±0.14 1.19
Atoh1 NM_007500.4 0.72±0.06 0.80±0.11 1.10
Neurod1 NM_010894.2 0.89±0.11 0.79±0.09 0.89
Gut peptides
GLP-2r NM_175681.2 0.74±0.14 0.97±0.07 1.31
GLP-1r NM_021332.2 0.78±0.15 0.79±0.10 1.02
Preproglucagon NM_008100.3 0.91±0.10 0.86±0.14 0.95
Lepr NM_146146.1 0.83±0.06 0.68±0.08* 0.82
PYY NM_145435.1 1.47±0.18* 1.16±0.10 0.79
DPPIV NM_010074.2 1.22±0.16 0.95±0.09 0.78
GIPr NM_001080815.1 1.30±0.20 0.92±0.15 0.70
GIP NM_008119.2 ND ND ND
Lipid metabolism
I-FABP NM_007980.2 0.97±0.15 1.06±0.13 1.10
PPARa NM_011144.5 1.02±0.20 0.71±0.09 0.70
FIAF NM_020581.1 0.92±0.14 0.52±0.10*y 0.57
Short chain fatty acid response
Cathelicidin NM_009921.1 0.49±0.12 0.96±0.30 1.95
GPR41 NM_001033316.2 0.88±0.13 1.27±0.14 1.45
GPR43 NM_146187.3 0.87±0.14 0.76±0.14 0.87
Endocannabinoid system
CB1 NM_007726.3 0.65±0.27 1.16±0.20 1.80
GRP119 NM_181751.2 0.99±0.14 1.20±0.22 1.22
GRP55 NM_001033290.2 0.84±0.19 1.03±0.14 1.22
CB2 NM_009924.3 1.87±0.23* 1.17±0.23 0.63
Other
RXRa NM_011305.3 0.83±0.10 0.93±0.07 1.12
GLUT-2 NM_031197.1 2.09±0.58 1.89±1.18 0.90
CRBPII NM_009034.3 0.91±0.16 0.81±0.13 0.89
Abbreviations: Atoh, atonal homolog; CB, cannabinoid receptor; COX, cyclooxygenase; CRBP, retinol binding protein; CT, control diet; DPPIV, dipeptidyl
peptidase IV; FIAF, fasting-induced adipose factor; GIP(r), gastric inhibitory polypeptide (receptor); GLP, glucagon-like peptide; GPR or GRP, G protein-coupled
receptor; HF, high fat diet; HF-AXOS, HF diet supplemented with arabinoxylan oligosaccharides; I-FABP, intestinal fatty acid binding protein; IFN, interferon;
IL, interleukin; ITF, trefoil factor 3; Lepr, leptin receptor; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; MUC, mucin;
ND, not detected or detected in few samples; Neurog, Neurogenin; Neurod, Neurogenic differentiation; NM, GenBank accession number; PPAR, peroxisome
proliferator-activated receptor; PYY, peptide YY; RXR, retinoid X receptor; TLR, toll-like receptor; TNF, tumour necrosis factor; ZO, zonula occludens.
Results obtained from TLDA analysis representing the ratio of mRNA abundance as compared with control mice (using the 2DCt method where DCt¼CtCt
RPL19). mRNAs were classified in function categories. Ratio represents mean fold change in abundance of HF-AXOS group relative to the HF group.
Mice were fed a HF diet or a HF diet supplemented with arabinoxylan oligosaccharides (HF-AXOS) for 8 weeks. *Po0.05 versus CT and yPo0.05 versus
HF (analysis of variance).
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Over the past 5 years, the gut microbiota is increasingly
considered as a symbiotic partner for the maintenance of health.28
Several data suggest that the activity of the gut microbiota is a
factor to take into account when assessing the risk factors related
to obesity, and associated disorders, such as dyslipidemia,
inﬂammation, insulin resistance and diabetes.6 - 8,11,29 - 31 The
hypothesis that speciﬁc modulation of the biﬁdobacteria commu-
nity in obesity is supported by several studies obtained in mice as
well as in humans.14,15,32 - 34 We previously showed that HF/
carbohydrate-free diet led to obesity and diabetes and changes
bacterial populations in the intestinal microbiota. Indeed, Biﬁdo-
bacterium spp. Bacteroides-related bacteria and Eubacterium
rectale --Clostridium coccoides group were reduced in the caecum
of mice fed a HF diet during 4 or 14 weeks.15,35 It was described
that among the different gut bacteria analysed, the metabolic
endotoxemia negatively correlated with the biﬁdobacteria
count.15 Here, we show that feeding mice during 8 weeks with
a HF diet containing carbohydrates (20% in energy), decreased the
dominant members of the mouse intestinal microbiota ---
Bacteroides-Prevotella spp. from the Bacteroidetes phylum. The
speciﬁc populations of lactobacilli from the Firmicutes phylum and
biﬁdobacteria from the Actinobacteria phylum were also reduced
upon HF feeding.36 AXOS supplementation led to a huge increase
of biﬁdobacteria (with a level even higher than control mice),
whereas lactobacilli number was further reduced in HF-AXOS
mice. This contrasting effect had never been described with other
prebiotic (inulin-type fructan) in HF diet-induced obese mice and
needs further investigations clearly focusing on speciﬁc changes
inside the Lactobacillus genus.15,37 The higher caecal content of
biﬁdobacteria was associated with improvement of metabolic
endotoxemia and inﬂammatory markers as described for inulin-
type fructan.14,15 We observed that an anti-inﬂammatory inter-
leukin (IL10) was upregulated in the colon tissue after HF-AXOS
treatment as compared with the control diet. The increase of both
plasma IL6 and F4/80 mRNA in the adipose tissue because of the
HF feeding were blunted due to AXOS supplementation.
Several mechanisms have been proposed in order to explain
the positive effect of the prebiotic approach in obesity models.
Among those hypotheses, the modulation of endocrine function
that occurs in prebiotic-fed animals, is a phenomenon that
contributes to the improvement of obesity and associated
disorders.7,8,16 The ingestion of inulin-type fructans has been
shown to increase the number of L cells in the proximal colon of
rats or mice, leading to the secretion of different peptides,
including GLP1, GLP2 and PYY. These gut peptides have a role in
the control of gut barrier, appetite and glucose homeo-
stasis.14,16,38,39 The resulting increase in GLP-2 contributes to the
improvement of gut barrier function, namely through the higher
expression of tight junction protein.14 Consequently, metabolic
endotoxemia was reduced in those obese mice fed with
prebiotic.14 In the present study, we observed that the tight
junction proteins ZO1 and claudin 3 were upregulated in the
colon after AXOS supplementation. More importantly, AXOS
treatment blunted the HF-induced LPS concentration determined
in the portal serum, supporting this hypothesis.
GLP-1 is a gut peptide able to regulate food intake and glucose
homeostasis.7,8 We have shown more detectable level of GLP-1 in
the portal serum of HF-AXOS group than in HF group. The level of
PYY, another satietogenic peptide, was also signiﬁcantly higher in
the portal plasma upon AXOS supplementation. Both effects
might be involved in the lower food intake observed in this study,
leading probably to the lower body weight gain and fat mass
development as already described for inulin-type fructan.15,16 The
HF diet-induced fasting hyperinsulinemia and the higher HOMA-IR
were signiﬁcantly decreased under AXOS supplementation. These
results suggest improved insulin sensitivity in mice fed with this
biﬁdogenic compound.
Due to its propionate-producing effect upon fermentation,
AXOS is proposed as a prebiotic prone to lower cholesterol and to
beneﬁcially affect fat metabolism of the host.21 However, we did
not observe any effect of AXOS on lipid proﬁles both in the liver
and in the plasma.
Several parameters suggested that the colon may be relevant in
the metabolic effects observed through the AXOS supplementa-
tion (the colon enlargement, the higher circulating satietogenic
peptides produced by the L cells in the colon, the higher
expression of a tight junction protein in the colon). Therefore, we
decided to explore several genes in this organ using a technique
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Figure 5. PCA. (a) Score plot of all parameters investigated in this
study in mice fed a standard diet (J), a high fat (HF) diet (K) or a
HF diet supplemented with arabinoxylan oligosaccharides
(HF-AXOS) ( ) for 8 weeks. (b) Projection of the parameters
significantly modified by AXOS treatment in the plane defined by
the two first PCs (loading plot). BW, body weight; IL, interleukin; PYY,
peptide YY; ZO, zonula occludens; SAT subcutaneous adipose tissue
weight; EAT, epididymal adipose tissue weight; LPS, endotoxemia;
FIAF, fasting-induced adipose factor; GLP-1, glucagon-like peptide-1;
HOMA, Homeostasis Model Assessment of insulin resistance.
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for high throughput screening in functional genomics by
simultaneously measuring mRNA expression of multiple genes
(TaqMan low-density array). We have shown that a protein
involved in tight junctions ---claudin3--- was signiﬁcantly upregu-
lated in the colonic tissue of AXOS-treated mice through this
technique. Tight junctions are important for the permeability
properties of epithelial and endothelial barriers as they restrict
diffusion along the paracellular space.40 They consist of trans-
membrane proteins such as claudins, which mediate adhesion and
barrier formation as well as selective paracellular diffusion. These
membrane proteins interact with a cytoplasmic plaque consisting
of junction adaptors, such as the zonula occludens proteins, that
contain multiple protein --protein interaction domains. In our
study, quantitative PCR analysis revealed that ZO1 was also
induced through the AXOS treatment. Such a junction adaptor
form a protein network that links the junction to the actin
cytoskeleton and recruits different types of signalling proteins that
regulate junction assembly and function as well as epithelial
proliferation and differentiation.40 Those results suggest that
AXOS improves gut barrier function and decreases gut perme-
ability.
AXOS also induced the expression of IL10 as compared with
control mice, which could therefore contribute to the higher level
of this anti-inﬂammatory cytokine in the serum. Concomitantly
with the lower endotoxemia, we postulate that the lower
inﬂammatory tone observed upon AXOS supplementation is the
consequence of the higher production of IL10 coming from the
colon.
PCA is often used to reduce the dimensionality of the data
proﬁles containing intercorrelated variables. Moreover, PCA aims
to display the maximum amount of variation in a data proﬁle
within a few PCs. Hence, score plots derived from PCA are useful
to ﬁnd similarities and contrasts between samples, whereas
correlations among variables can be identiﬁed in loading plots. In
the present study, score plots revealed that control mice and
AXOS-treated mice were closely associated considering all
parameters analysed in the present study, whereas HF-fed mice
were more distant. The loading plots of PCA indicate relationships
between gut microbes and metabolic parameters involved in
obesity-associated disorders such as caecal content of biﬁdobac-
teria and endotoxemia. The opposition between caecal content of
lactobacilli and colonic expression of IL10 suggests that it would
be interesting to evaluate lactobacilli with inﬂammatory effects in
prebiotic-treated animals. At present, we cannot conclude that
speciﬁc genera, classes or species of bacteria are positively or
negatively associated with the obese phenotype.7 The aim of this
study was to investigate the prebiotic effect of AXOS related to its
biﬁdogenic effect in a context of obesity. We may not exclude the
participation of other gut microbes in the interesting effects
observed as evoked for examples with Roseburia.25,26 Other
fermentable carbohydrates can exert similar effect in HF diet-fed
mice, than the one described with AXOS in our study. Resistant
starch, when added at the level of 30%, is able to decrease body
fat in HF (7%) diet-fed mice, and this effect seems to be rather
related to caecal fermentation (decrease in pH), than to a decrease
in energy intake.41,42 In addition, resistant starch also promote gut
peptides involved in appetite and metabolic regulation.43 The
relation between resistant starch feeding and the gut microbial
composition could be very interesting to analyse further, in order
to extend the concept of prebiotic to other carbohydrates that are
part of the current and healthy diet.
From this study it can be concluded that, AXOS derived from
wheat bran has a huge biﬁdogenic effect as previously shown for
inulin-type fructan.17 This prebiotic effect was accompanied by an
improvement of the HF-induced body weight gain, fat mass
development, hyperinsulinemia, insulin resistance, endotoxemia
and inﬂammatory disorders in a model of HF diet-induced obesity.
The higher levels of peptides coming from the colon seemed to be
the key molecular targets. Indeed, the higher levels of GLP-1 and
PYY measured in the portal serum of mice supplemented with
AXOS were associated with the lower energy intake. On the other
hand, the gut function dependent on GLP-2 was improved (higher
tight junction proteins expression) upon AXOS treatment.
In view of correlation and PCA analyses, and consistent with our
previous studies with the prebiotic inulin-type fructan, we
postulate that all these beneﬁcial effects can be related to
modulation of gut microbiota such as higher content in
biﬁdobacteria in the caecum. Altogether, these ﬁndings support
a role for wheat-derived AXOS as interesting non-digestible
nutrients with prebiotic properties related to prevention of
obesity and related inﬂammatory disorders.
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